Treatment of chronic hepatitis B with lamivudine

Journal of the College of Physicians and Surgeons Pakistan

Volumn 15, Issue 2, 2005, Pages 78-80

  Khokhar, Nasir ^a   Gill, Muzaffar Lateef ^a   Alam, Ali Yawar ^a  

^a SHIFA INTERNATIONAL HOSPITAL   (Pakistan)

Author keywords

Chronic hepatitis B; Interferon; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PAKISTAN; POLYMERASE CHAIN REACTION; POPULATION DISTRIBUTION; POPULATION RESEARCH; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; PAKISTAN; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 17444427118     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lok ASF. Chronic hepatitis B. N Engl J Med 2002; 346 1682-3.
2. Andre F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 2000; 18 (suppl 1): S20-2.
3. Ghavanini AA, Sabri MR. Hepatitis B surface antigen and anti-hepatitis C antibodies among blood donors of Islamic Republic of Iran. East Mediterr Health J 2000; 6: 1114-6.
4. Al-Shaikh S, Saeed L, Eltom A, Buchel E. The seroprevalence of hepatitis B surface antigen (HBsAg) and hepatitis C antibodies (anti-HCV) in the United Arab Emirates (UAE). J Gastroenterol Hepatol 2002; 17 (suppl) A-348.
5. Qasmi SA, Aqeel S, Ahmed M, Alam SI, Ahmed A. Detection of hepatitis B viruses in normal individuals of Karachi. J Coll Physicians Surg Pak 2000; 10: 467-9.
6. Mujeeb SA, Aamir K, Mehmood K. Seroprevalence of HBV, HCV and HIV infections among college going first time voluntary blood donors. J Pak Med Assoc 2000; 50: 269-70.
7. Asif N, Khokhar N, Ilahi F. Seroprevalence of HBV, HCV and HIV infection among voluntary non-remunerated and replacement donors in Northern Pakistan. Pak J Med Sci 2004; 20: 24-8.
8. Khokhar N, Gill ML, Malik GJ. Seroprevalence of HBV and HCV in general population of Pakistan (in Press).
9. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23: 47-58.
10. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaskan natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-68.
11. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
12. Bortolotti F, Jara P, Crivellaro C, Hierro L, Cadrobbi P, Frauca E, et al. Outcomes of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998; 29 184-90.
13. Schalm S, DeMann R, Janssen H. Combination and newer therapies for chronic hepatitis B. J Gastroenterol Hepatol 2002; 17 (suppl 3): S338-S341.
14. East International Consensus Conference on hepatitis B. J Hepatol 2003; 38: 533-40.
15. Asian-Pacific Consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003; 18 239-45.
16. Abbas Z, Jafri W, Shah SHA, Khokhar N, Zuberi SJ. Members of consensus panel. PSG consensus statement on management of hepatitis B virus infection - 2003. J Pak Med Assoc 2004; 54: 150-8.
17. Dienstag JL, Schiff ER, Wright TL. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
18. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
19. Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003; 39(suppl 1): S111-5.
20. Liaw YF, Leung N, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-80.
21. Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000; 61: 398-402.
22. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003; 23: 81-8.
23. Chein R, Liaw YF, Atkins M. Pretherapy alanine aminotransferase level as a determinant for hepatitis Be antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 770-4.
24. Rosenberg PM, Dienstag JL. Therapy with nucleoside analogues for hepatitis B virus infection. Clin Liver Dis 1999; 3: 349-61.
25. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003; 46: 182-9.
26. Mailliard ME, Gollan JL. Suppressing hepatitis B without resistance - so far, so good. N Engl J Med 2003; 348: 898-50.